



**The ACME Laboratories Ltd.**

MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001:2008 CERTIFIED COMPANY

Ref. No. ACME /CA/CS/0143/2017

13 November 2017

**The Chairman**

Bangladesh Securities and Exchange Commission (BSEC)  
Plot No. E-C/6, Agargaon,  
Sher-e-Bangla Nagar  
Dhaka-1207

**Subject: Audited Status Report on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd.**

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report (as per revised format) on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 80<sup>th</sup> Meeting held on 12 November 2017 for your kind perusal and record please.

Thanking you and assuring of our best attention for all the time to come.

  
(Mizanur Rahman Sinha)  
Managing Director

**Enclosure:** As stated above



Copy to:

01. The Managing Director, Dhaka Stock Exchange Limited
02. The Managing Director, Chittagong Stock Exchange Limited
03. The Chief Executive Officer, ICB Capital Management Limited

**Corporate Office:**

**Court de la ACME**

1/4, Kallayanpur, Mirpur Road  
Dhaka-1207, Bangladesh.  
Phone: +88-02-9004194-6  
Fax: +88-02-9016872  
E-mail: headoffice@acmeglobal.com

[www.acmeglobal.com](http://www.acmeglobal.com)

**Plant:**

Dhamrai, Dhaka, Bangladesh  
Phone: +88-02-7730881-2  
88-02-7730816-7, 7730142  
Fax: +88-02-7730141  
E-mail: plant@acmeglobal.com

# Auditors' Report



Name of Client

**The ACME Laboratories Ltd.**  
**Utilization of IPO Proceeds**  
**for the month ended 31 October 2017**

**পিনাকী এণ্ড কোম্পানী**  
**Pinaki & Company**

**AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh**  
**Tel # 966-0944, 966-5095, Fax # 88-02-9672726**  
**E-mail : pinaki\_co@yahoo.com**





**AUDITORS' REPORT**  
*on*  
**Utilization of IPO Proceeds**

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of **The ACME Laboratories Ltd.** for the month ended 31 October 2017.

**Management's Responsibility for the IPO proceeds Utilization**

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

**Auditor's Responsibility**

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with Bangladesh Standards on Auditing (BSA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Opinion**

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 gives a true and fair view of the statement for the month ended 31 October 2017 and comply with the resolution of 40th AGM of the company.

**As per TOR, We draw attention to the following matter:**

1. The Company has utilized cumulative amounting Tk. 493,701,399 up to 31 October 2017 in respect of Steroid and Hormone Project.
2. The Company has utilized cumulative amounting Tk. 77,418,111 up to 31 October 2017 in respect of Penicillin Project.

Independent Associate Member of Thakur, Vaidyanath Aiyar & Co., Chartered Accountants, New Delhi, India.

Dhaka : AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh

Phone # 966-0944, 966-5095, E-mail : pinaki\_co@yahoo.com Fax # 88-02-9672726, Mobile # 01711-364850, 01711-106302



3. The Company has also utilized cumulative amounting Tk. 42,818,652 up to 31 October 2017 in respect of Active Pharmaceuticals Ingredients (API) Project.

**We also state that:**

- IPO proceeds have been utilized for the purposes as specified in the resolution of 40<sup>th</sup> AGM of the company;
- IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- Utilization of IPO proceeds is being under completion within the time frame as specified in the resolution of 40<sup>th</sup> AGM of the company;
- Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the resolution of 40<sup>th</sup> AGM of the company;
- Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Date : 13 November, 2017  
Dhaka.

*pinaki & Co.*  
13.11.17

**Pinaki & Company**  
Chartered Accountants





**Report on Utilization of IPO Proceeds**  
For the Month of October 2017

**Name of the Company:**

Amount (BDT) of capital raised through IPO:

Date of Close of Subscription:

Proceeds Receiving Date:

Last Date of Full Utilization of IPO Fund as per prospectus/40th AGM

: The ACME Laboratories Ltd.

: BDT 4,096,000,000 (Net amount received BDT 4,095,015,601.38 net of foreign currency conversion loss)

: 21 April 2016

: 11 April 2016 to 21 April 2016

: As stated in time line as per prospectus and revised time line columns

S.L	Purpose mentioned in the Prospectus	Time line as per Prospectus	Revised Time line	Amount as per Prospectus	Amount as per revised utilization Plan	Status of Utilization		Remarks
						Total Utilized Amount	Total un utilized amount	
1	Steroid and Hormone Project	Within 2 years of receiving IPO fund, i.e., 2018	N/A	1,358,000,000	1,358,000,000	493,701,399	864,298,601	63.64%
2	Oncology project converted into Penicillin Project (Revised)	Within 2.5 years of receiving IPO fund	Within the month of March 2018	1,141,000,000	400,000,000	77,418,111	322,581,889	80.65%
3	Ayurvedic, Modern Herbal and Neutraceuticals converted into Active Pharmaceuticals Ingredients (API) (Revised)	Within 2.5 years of receiving IPO fund	Within 2-3 years after getting permission from the Ministry of Industries	1,745,500,000	1,355,228,292	42,818,652	1,312,409,640	96.84%
4	Repayment of Bank Borrowing (Revised)	N/A	N/A	N/A	1,360,000,000	1,360,000,000	-	0.00%
5	IPO Expenses	N/A	N/A	68,291,870	68,291,870	68,291,870	-	0.00%
<b>Total</b>						<b>4,312,791,870</b>	<b>4,541,520,162</b>	<b>44.97%</b>
						<b>2,042,230,032</b>	<b>2,499,290,130</b>	<b>55.03%</b>

Percentage (Interest on FDR to be matured on 27 December 2017)

Interest on IPO Proceeds in BDT (from FDR & SND)

Un-Utilized IPO Proceeds with interest income in BDT

83,457,256

2,136,242,825

On Behalf of Board

(Fouzia Haque, FCA)

Independent Director & Chairman of the Audit Committee

(Mizanur Rahman Sinha)

Managing Director

(Afzalur Rahman Sinha)

Chairman

Pinaki & Company  
Chartered Accountants